213,240 Shares in Ventyx Biosciences, Inc. (NASDAQ:VTYX) Acquired by Woodline Partners LP

Woodline Partners LP acquired a new position in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 213,240 shares of the company's stock, valued at approximately $467,000. Woodline Partners LP owned approximately 0.30% of Ventyx Biosciences as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the stock. Catalina Capital Group LLC purchased a new stake in shares of Ventyx Biosciences in the 4th quarter valued at about $25,000. AXQ Capital LP purchased a new stake in shares of Ventyx Biosciences in the 4th quarter valued at about $29,000. Palumbo Wealth Management LLC raised its holdings in shares of Ventyx Biosciences by 97.1% in the 4th quarter. Palumbo Wealth Management LLC now owns 23,932 shares of the company's stock valued at $52,000 after acquiring an additional 11,792 shares in the last quarter. MetLife Investment Management LLC raised its holdings in shares of Ventyx Biosciences by 76.0% in the 4th quarter. MetLife Investment Management LLC now owns 26,731 shares of the company's stock valued at $59,000 after acquiring an additional 11,543 shares in the last quarter. Finally, Velan Capital Investment Management LP purchased a new stake in shares of Ventyx Biosciences in the 4th quarter valued at about $77,000. Hedge funds and other institutional investors own 97.88% of the company's stock.

Ventyx Biosciences Price Performance

Shares of NASDAQ:VTYX traded down $0.14 on Friday, hitting $1.68. The company's stock had a trading volume of 1,270,791 shares, compared to its average volume of 1,344,373. The company has a 50-day simple moving average of $1.25 and a 200 day simple moving average of $1.72. Ventyx Biosciences, Inc. has a 1 year low of $0.78 and a 1 year high of $5.66. The company has a market capitalization of $119.19 million, a PE ratio of -0.71 and a beta of 0.73.

Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.09. On average, equities research analysts expect that Ventyx Biosciences, Inc. will post -2.09 earnings per share for the current fiscal year.

Ventyx Biosciences Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.